The first protein‐binding allosteric RNA‐cleaving DNAzyme (RCD) obtained by direct in vitro
selection against eosinophil peroxidase (EPX), a validated marker for airway eosinophilia, is …

Background: New anti-IL-5 antibodies, mepolizumab and benralizumab, have recently been
approved for severe asthma, sharing the same inclusion criteria. Objective: To contribute on …

Abstract Purpose of Review Eosinophils are short-lived granulocytes that contain a variety of
proteins and lipids traditionally associated with host defense against parasites. The primary …

Asthma is a chronic complex pulmonary disease characterized by airway inflammation,
remodeling, and hyperresponsiveness. Vascular endothelial growth factor (VEGF) and …

Background Clinical heterogeneity may exist within asthma subtypes defined by
inflammatory markers. However, the heterogeneity of neutrophilic asthma (NA) remains …

Around three million patients die due to airway inflammatory diseases each year. The most
notable of these diseases are asthma and chronic obstructive pulmonary disease (COPD) …

Eosinophilic asthma (EA) is a common subtype of asthma and often progresses to severe
disease. In order to understand its pathogenesis, targeted next-generation gene sequencing …

MicroRNAs (miRNAs) are short single-stranded RNAs that have pivotal roles in disease
pathophysiology through transcriptional and translational modulation of important genes. It …

Omalizumab is a humanized monoclonal antibody which binds to human immunoglobulins
E (IgE), thus preventing their interactions with both high affinity and low affinity IgE receptors …

Background Several new treatments for severe asthma have become available in the last
decade; yet, little data exist to guide their use in specific patient populations. Objective A …